Physician profile
Thomas A John
NPI 1497837033
$3,347.71
in general payments reported to CMS, 2019-2025
29 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $347 · 2021: $192 · 2022: $149 · 2023: $527 · 2024: $664 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,722.82 | 2019-2025 | |
| Stryker Corporation | $169.53 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ferring Pharmaceuticals INC. | $130.89 | 2024-2025 | Rebyota |
| Vivus LLC | $129.51 | 2022-2025 | Pancreaze |
| Enterra Medical, INC. | $127.91 | 2025 | |
| Madrigal Pharmaceuticals | $105.24 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $100.72 | 2024-2025 | Terlivaz |
| Braintree Laboratories, INC. | $85.93 | 2020-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $76.14 | 2020-2024 | |
| Janssen Biotech, INC. | $71.62 | 2022-2025 | Stelara, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.54 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $66.35 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $55.87 | 2023 | Fujifilm |
| Ardelyx, INC. | $54.16 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $44.03 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.66 | 2023-2025 | Entyvio, Eohilia |
| Novo Nordisk INC | $37.22 | 2020-2025 | Wegovy |
| Medtronic, INC. | $35.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $32.59 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $24.23 | 2024 | Dupixent |
| Ultragenyx Pharmaceutical INC. | $22.94 | 2022 | |
| Merck Sharp & Dohme LLC | $21.41 | 2025 | Bridion |
| Idorsia Pharmaceuticals US INC | $20.32 | 2023 | Quviviq |
| Celgene Corporation | $19.45 | 2022 | |
| Boston Scientific Corporation | $19.34 | 2019 | |
| Dentsply Ih Ab | $19.24 | 2024 | Navina Rectal Catheter Set Regular |
| Exact Sciences Corporation | $18.52 | 2025 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $13.68 | 2025 | |
| Ethicon US, LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.